[Clinical effect of Xiongshao capsule on preventing restenosis post-PTCA or/and stenting].
To evaluate the effect of Xiongshao capsule (XSC) in preventing clinical and angiographic restenosis after coronary angioplasty or/and stenting. Sixty-five coronary heart disease (CHD) patients with successful angioplasty or and stenting were randomly divided into the control group (37 cases, routine treatment) and the XSC group (28 cases, routine treatment plus XSC). The recurrent of angina, changing of blood stasis syndrome score (BSSS) and coronary angiography within 6 months after coronary angioplasty or/and stenting were observed. Recurrent angina occurred in 6 out of 28 patients in the XSC group, which was much better than that in the control group, 18 out of 37 patients (P < 0.05). Follow-up angiography was performed in 26 including 10 patients in the XSC group (restenosis was observed in 4 cases), and 16 cases in the control group (restenosis in 13 cases), there was significant difference between the XSC group and the control group (P < 0.05). For BSSS at follow-up, XSC group was much lower than that of the control group (P < 0.01). Logistic regress analysis showed the combination with XSC and the base-line BSSS were important affecting factors on the occurrence of restenosis (P < 0.05). The odds ratio of the occurrence of angiographic restenosis (BSSS > 25 to BSSS < or = 25) was 6.5. XSC could markedly reduce the occurrence of restenosis, recurrence of angina and improve the condition of blood stasis after coronary angioplasty or/and stenting. The severity of blood stasis syndrome was an important affecting factor on the occurrence of restenosis. BSSS > 25 can be served as one of the predicting factors of the occurrence of restenosis after coronary angioplasty or/and stenting.